Fenfluramine May Improve Executive Functioning in LGS, Showing Benefit Beyond Seizure Control Adult patients with LGS taking fenfluramine showed meaningful improvement in measures of executive functioning.

Caregivers observed clinically meaningful improvements in executive functioning (EF) in a greater percentage of adults with Lennox-Gastaut syndrome (#LGS) receiving #Fenfluramine compared with those receiving placebo.

Read more: https://bit.ly/3No00eL

#InternationalEpilepsyDay #RareDiseaseMonth

Fenfluramine May Improve Executive Functioning in LGS, Showing Benefit Beyond Seizure Control Adult patients with LGS taking fenfluramine showed meaningful improvement in measures of executive functioning.

Caregivers observed clinically meaningful improvements in executive functioning (EF) in a greater percentage of adults with Lennox-Gastaut syndrome (#LGS) receiving #Fenfluramine compared with those receiving placebo. @amepilepsysoc.bsky.social

Read here: https://bit.ly/3No00eL

UCB Announces Positive Phase 3 Study Results for Fenfluramine in Treating CDKL5 Deficiency Disorder UCB has revealed promising findings from the GEMZ phase 3 trial, demonstrating that fenfluramine significantly lessens seizure frequency in patients with CDKL5 deficiency disorder.

UCB Announces Positive Phase 3 Study Results for Fenfluramine in Treating CDKL5 Deficiency Disorder #United_States #Atlanta #UCB #fenfluramine #CDKL5_Deficiency

UCB Unveils Positive Findings from GEMZ Phase 3 Study on Fenfluramine for Seizures UCB revealed promising results from its GEMZ Phase 3 study, showing fenfluramine effectively reduces seizure frequency in patients with CDKL5 Deficiency Disorder.

UCB Unveils Positive Findings from GEMZ Phase 3 Study on Fenfluramine for Seizures #USA #Atlanta #fenfluramine #CDKL5_Deficiency #GEMZ_Study

UCB Reveals Promising Phase 3 Study Results for Fenfluramine in CDKL5 Deficiency Disorder at AES 2025 At the American Epilepsy Society meeting, UCB showcased phase 3 study results that demonstrate fenfluramine's effectiveness in reducing seizures in CDKL5 Deficiency Disorder.

UCB Reveals Promising Phase 3 Study Results for Fenfluramine in CDKL5 Deficiency Disorder at AES 2025 #USA #Atlanta #UCB #CDKL5 #fenfluramine

The combination of FFA and BR is effective in patients with DS, achieving seizure reductions comparable to other FFA-based regimens.
doi.org/10.1002/epi4...

#epilepsy #epilepsiaopen #epilepsia #Dravetsyndrome #druginteractions #fenfluramine #potassiumbromide #seizures

The clinical effects of fenfluramine result from the combined actions of two pairs of enantiomers (d- and l-fenfluramine and d- and l-norfenfluramine).
doi.org/10.1111/epi....

#epilepsy #ILAE #epilepsia #concentrationresponserelationships #enantiomers #fenfluramine #MESmodel #mice

UCB reports success in phase 3 study of fenfluramine for CDD - PharmaTimes Positive trial results offer hope for those with ultra-rare epileptic disorder

#UCB #fenfluramine #CDD #ultrarareepilepticdisorder #ultrararediseases #CDKL5deficiencydisorder #developmentalandepilepticencephalopathy #DEE #earlyonsetepilepsy #neurodevelopmentaldelays #developmentalandepilepticencephalopathies #CDKL5gene
pharmatimes.com/news/ucb-rep...

UCB Reports Promising Phase 3 Results for Fenfluramine in CDKL5 Deficiency Disorder and Future Plans UCB has announced encouraging Phase 3 trial results for fenfluramine in treating CDKL5 deficiency disorder, highlighting their commitment to innovation in this area.

UCB Reports Promising Phase 3 Results for Fenfluramine in CDKL5 Deficiency Disorder and Future Plans #United_States #Atlanta #UCB #CDKL5 #fenfluramine

First non-cannabis treatment for rare form of epilepsy made available on NHS The National Institute for Health and Care Excellence (NICE) has announced that the first non-cannabis-based treatment for a rare form of epilepsy will be available for NHS patients in England. It…

NICE has recommended #fenfluramine for seizures associated with Lennox-Gastaut syndrome

#lennoxgestaut #LGS